Ocrevus and Tumor marker increased - a phase IV clinical study of FDA data

Summary:

Tumor marker increased is reported as a side effect among people who take Ocrevus (ocrelizumab), especially for people who are female, 40-49 old, also take Vimpat, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Tumor marker increased when taking Ocrevus. It is created by eHealthMe based on reports of 56,539 people who have side effects when taking Ocrevus from the FDA, and is updated regularly.

What is Ocrevus?

Ocrevus has active ingredients of ocrelizumab. eHealthMe is studying from 56,583 Ocrevus users. Check the latest studies of Ocrevus.

What is Tumor marker increased?

Tumor marker increased is found to be associated with 351 drugs and 388 conditions by eHealthMe. Check the latest studies of Tumor marker increased.

On Jul, 09, 2026

56,539 people reported to have side effects when taking Ocrevus.
Among them, 28 people (0.05%) have Tumor marker increased.

Could Ocrevus cause Tumor marker increased?

Among these 28 people:

What is the gender of people who have Tumor marker increased when taking Ocrevus? *

female: 100 %
male: 0.0 %

What is the age of people who have Tumor marker increased when taking Ocrevus? *

What are other drugs people take besides Ocrevus? *

What are other side effects people have besides Tumor marker increased? *

Fatigue (feeling of tiredness): 26 people, 92.86%
High Blood Pressure: 25 people, 89.29%
Lipoedema (abnormally fat below the waist): 24 people, 85.71%
Peripheral Swelling: 24 people, 85.71%
Balance Disorder: 24 people, 85.71%
Dermatitis Allergic (inflammation of the skin due allergic reaction): 24 people, 85.71%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 24 people, 85.71%
Nasopharyngitis (inflammation of the nasopharynx): 24 people, 85.71%
Otitis Media (inflammation of the middle ear): 24 people, 85.71%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 24 people, 85.71%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 28 people, 100.00%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 24 people, 85.71%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 24 people, 85.71%
Depression: 24 people, 85.71%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 10.71%
Thyroid Cancer: 2 people, 7.14%
Blood Potassium Decreased: 2 people, 7.14%
Blood Magnesium Decreased: 2 people, 7.14%
High Blood Pressure: 1 person, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Ocrevus and have Tumor marker increased?

- Check whether Tumor marker increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ocrevus:

Ocrevus (56,583 reports)

Browse all side effects of Ocrevus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tumor marker increased:

Tumor marker increased (351 drugs)

Browse all the conditions that are associated with Tumor marker increased:

Tumor marker increased (388 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ocrelizumab (the active ingredients of Ocrevus) and Ocrevus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.